Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes

Authors

Guillermo Montalban-Bravo, University of Texas MD Anderson Cancer Center
Elias Jabbour, University of Texas MD Anderson Cancer Center
Caleb Class, University of Texas MD Anderson Cancer Center
Nicholas Short, University of Texas MD Anderson Cancer Center
Rashmi Kanagal-Shamanna, University of Texas MD Anderson Cancer Center
Tapan Kadia, University of Texas MD Anderson Cancer Center
Gautam Borthakur, University of Texas MD Anderson Cancer Center
Naveen Pemmaraju, University of Texas MD Anderson Cancer Center
Koji Sasaki, University of Texas MD Anderson Cancer Center
Zeev Estrov, University of Texas MD Anderson Cancer Center
Jorge Cortes, University of Texas MD Anderson Cancer Center
Farhad Ravandi, University of Texas MD Anderson Cancer Center
Yesid Alvarado, University of Texas MD Anderson Cancer Center
Rami Komrokji, Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Mikkael Sekeres, Cleveland Clinic
David Steensma, Harvard University
Amy DeZern, Johns Hopkins University
Gail Roboz, NewYork–Presbyterian Hospital
Hui Yang, University of Texas MD Anderson Cancer Center
Hagop Kantarjian, University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero, University of Texas MD Anderson Cancer Center

Document Type

Article

Publication Date

November 2019

Publication Title

Blood

First Page

1715

Last Page

1715

DOI

10.1182/BLOOD-2019-129141

Recommended Citation

Montalban-Bravo, Guillermo; Jabbour, Elias; Class, Caleb; Short, Nicholas; Kanagal-Shamanna, Rashmi; Kadia, Tapan; Borthakur, Gautam; Pemmaraju, Naveen; Sasaki, Koji; Estrov, Zeev; Cortes, Jorge; Ravandi, Farhad; Alvarado, Yesid; Komrokji, Rami; Sekeres, Mikkael; Steensma, David; DeZern, Amy; Roboz, Gail; Yang, Hui; Kantarjian, Hagop; and Garcia-Manero, Guillermo, "Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes" (2019). Scholarship and Professional Work – COPHS. 267.
https://digitalcommons.butler.edu/cophs_papers/267